{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:49:46Z","timestamp":1793227786554,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-022-00474-0","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T14:02:42Z","timestamp":1651500162000},"page":"166-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5005-1995","authenticated-orcid":false,"given":"Dimitrios G.","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0176-3598","authenticated-orcid":false,"given":"Olga","family":"Giouleme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-3118","authenticated-orcid":false,"given":"Georgios S.","family":"Germanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-594X","authenticated-orcid":false,"given":"Antonis","family":"Goulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","volume":"69","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69:564\u20138. https:\/\/doi.org\/10.1136\/gutjnl-2019-318813.","journal-title":"Gut"},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.metabol.2015.12.009","volume":"65","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metabolism. 2016;65:1007\u201316. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.009.","journal-title":"Metabolism"},{"key":"474_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","volume":"52","author":"E Makri","year":"2021","unstructured":"Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 2021;52:25\u201337. https:\/\/doi.org\/10.1016\/j.arcmed.2020.11.010.","journal-title":"Arch Med Res"},{"key":"474_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/apt.16575","volume":"54","author":"SA Polyzos","year":"2021","unstructured":"Polyzos SA, Kechagias S, Tsochatzis E. Review article: non-alcoholic fatty liver disease and cardiovascular diseases\u2014associations and treatment considerations. Aliment Pharmacol Ther. 2021;54:1013\u201355. https:\/\/doi.org\/10.1111\/apt.16575.","journal-title":"Aliment Pharmacol Ther"},{"key":"474_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"G Whitlock","year":"2009","unstructured":"Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(09)60318-4.","journal-title":"Lancet"},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/obr.12407","volume":"17","author":"L Li","year":"2016","unstructured":"Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17:510\u20139. https:\/\/doi.org\/10.1111\/obr.12407.","journal-title":"Obes Rev"},{"key":"474_CR7","doi-asserted-by":"publisher","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42:92\u2013108. https:\/\/doi.org\/10.23736\/S0391-1977.16.02563-3.","DOI":"10.23736\/S0391-1977.16.02563-3"},{"key":"474_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312.","journal-title":"Gastroenterology"},{"key":"474_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154413","volume":"113","author":"SA Polyzos","year":"2020","unstructured":"Polyzos SA, Kang ES, Tsochatzis EA, Kechagias S, Ekstedt M, Xanthakos S, et al. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism. 2020;113: 154413. https:\/\/doi.org\/10.1016\/j.metabol.2020.154413.","journal-title":"Metabolism"},{"key":"474_CR11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1080\/14656566.2016.1225727","volume":"17","author":"G Mintziori","year":"2016","unstructured":"Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother. 2016;17:1937\u201346. https:\/\/doi.org\/10.1080\/14656566.2016.1225727.","journal-title":"Expert Opin Pharmacother"},{"key":"474_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154203","volume":"111S","author":"SA Polyzos","year":"2020","unstructured":"Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020;111S: 154203. https:\/\/doi.org\/10.1016\/j.metabol.2020.154203.","journal-title":"Metabolism"},{"key":"474_CR13","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","volume":"24","author":"S Leoni","year":"2018","unstructured":"Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol. 2018;24:3361\u201373. https:\/\/doi.org\/10.3748\/wjg.v24.i30.3361.","journal-title":"World J Gastroenterol"},{"key":"474_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014.","journal-title":"Metabolism"},{"key":"474_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cld.2015.10.008","volume":"20","author":"WN Hannah Jr","year":"2016","unstructured":"Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20:339\u201350. https:\/\/doi.org\/10.1016\/j.cld.2015.10.008.","journal-title":"Clin Liver Dis"},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367\u201378. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.","journal-title":"Gastroenterology"},{"key":"474_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","volume":"78","author":"J Upadhyay","year":"2018","unstructured":"Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism. 2018;78:13\u201342. https:\/\/doi.org\/10.1016\/j.metabol.2017.08.010.","journal-title":"Metabolism"},{"key":"474_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/dom.14569","volume":"24 Suppl 2","author":"N Finer","year":"2022","unstructured":"Finer N. Weight loss interventions and NAFLD: optimising liver outcomes. Diabetes Obes Metab. 2021. https:\/\/doi.org\/10.1111\/dom.14569.","journal-title":"Diabetes Obes Metab"},{"key":"474_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.phrs.2018.09.025","volume":"137","author":"F Bifari","year":"2018","unstructured":"Bifari F, Manfrini R, Dei Cas M, Berra C, Siano M, Zuin M, et al. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res. 2018;137:219\u201329. https:\/\/doi.org\/10.1016\/j.phrs.2018.09.025.","journal-title":"Pharmacol Res"},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trsl.2020.07.008","volume":"227","author":"E Somm","year":"2021","unstructured":"Somm E, Montandon SA, Loizides-Mangold U, Ga\u00efa N, Lazarevic V, De Vito C, et al. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. Transl Res. 2021;227:75\u201388. https:\/\/doi.org\/10.1016\/j.trsl.2020.07.008.","journal-title":"Transl Res"},{"key":"474_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","volume":"46","author":"SA Polyzos","year":"2012","unstructured":"Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol. 2012;46:272\u201384. https:\/\/doi.org\/10.1097\/MCG.0b013e31824587e0.","journal-title":"J Clin Gastroenterol"},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"Lancet"},{"key":"474_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.diabet.2018.08.001","volume":"44","author":"HS Bajaj","year":"2018","unstructured":"Bajaj HS, Brown RE, Bhullar L, Sohi N, Kalra S, Aronson R. SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes. Diabetes Metab. 2018;44:493\u20139. https:\/\/doi.org\/10.1016\/j.diabet.2018.08.001.","journal-title":"Diabetes Metab"},{"key":"474_CR24","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"key":"474_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54:1150\u201361. https:\/\/doi.org\/10.1111\/apt.16608.","journal-title":"Aliment Pharmacol Ther"},{"key":"474_CR26","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1038\/ajg.2010.363","volume":"105","author":"PR Kenny","year":"2010","unstructured":"Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol. 2010;105:2707\u20139. https:\/\/doi.org\/10.1038\/ajg.2010.363.","journal-title":"Am J Gastroenterol"},{"key":"474_CR27","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020;63:2434\u201345. https:\/\/doi.org\/10.1007\/s00125-020-05265-7.","journal-title":"Diabetologia"},{"key":"474_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005325","volume":"4","author":"LL Gluud","year":"2014","unstructured":"Gluud LL, Knop FK, Vilsboll T. Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open. 2014;4: e005325. https:\/\/doi.org\/10.1136\/bmjopen-2014-005325.","journal-title":"BMJ Open"},{"key":"474_CR29","doi-asserted-by":"publisher","first-page":"22063","DOI":"10.1038\/s41598-021-01663-y","volume":"11","author":"S Ghosal","year":"2021","unstructured":"Ghosal S, Datta D, Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 2021;11:22063. https:\/\/doi.org\/10.1038\/s41598-021-01663-y.","journal-title":"Sci Rep"},{"key":"474_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/jgh.13026","volume":"31","author":"LJ Carbone","year":"2016","unstructured":"Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:23\u201331. https:\/\/doi.org\/10.1111\/jgh.13026.","journal-title":"J Gastroenterol Hepatol"},{"key":"474_CR31","doi-asserted-by":"publisher","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11. https:\/\/doi.org\/10.3390\/metabo11020073.","DOI":"10.3390\/metabo11020073"},{"key":"474_CR32","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.4239\/wjd.v12.i9.1576","volume":"12","author":"YZ Huang","year":"2021","unstructured":"Huang YZ, Yang GY, Wang C, Chen XY, Zhang LL. Effectiveness of drug interventions in nonalcoholic fatty liver disease: a network meta-analysis. World J Diabetes. 2021;12:1576\u201386. https:\/\/doi.org\/10.4239\/wjd.v12.i9.1576.","journal-title":"World J Diabetes"},{"key":"474_CR33","doi-asserted-by":"publisher","unstructured":"Napoli R, Avogaro A, Formoso G, Piro S, Purrello F, Targher G, et al. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutr Metab Cardiovasc Dis. 2021;31:3257\u201370. https:\/\/doi.org\/10.1016\/j.numecd.2021.08.039.","DOI":"10.1016\/j.numecd.2021.08.039"},{"key":"474_CR34","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","volume":"19","author":"M Monami","year":"2017","unstructured":"Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017;19:1233\u201341. https:\/\/doi.org\/10.1111\/dom.12926.","journal-title":"Diabetes Obes Metab"},{"key":"474_CR35","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.dsx.2020.09.030","volume":"14","author":"E Makri","year":"2020","unstructured":"Makri E, Kita M, Goulas A, Papaioannidou P, Efstathiadou ZA, Adamidou F, et al. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2020;14:1913\u20139. https:\/\/doi.org\/10.1016\/j.dsx.2020.09.030.","journal-title":"Diabetes Metab Syndr"},{"key":"474_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","volume":"53","author":"J Kumar","year":"2021","unstructured":"Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, et al. Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Dig Liver Dis. 2021;53:44\u201351. https:\/\/doi.org\/10.1016\/j.dld.2020.08.021.","journal-title":"Dig Liver Dis"},{"key":"474_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1365-2036.2004.02153.x","volume":"20","author":"SA Harrison","year":"2004","unstructured":"Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004;20:623\u20138. https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02153.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"474_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/gut.2006.106021","volume":"56","author":"N Assy","year":"2007","unstructured":"Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut. 2007;56:443\u20134. https:\/\/doi.org\/10.1136\/gut.2006.106021.","journal-title":"Gut"},{"key":"474_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/hep.22575","volume":"49","author":"SA Harrison","year":"2009","unstructured":"Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49:80\u20136.","journal-title":"Hepatology"},{"key":"474_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/br.2018.1100","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2018;9:90\u20136. https:\/\/doi.org\/10.3892\/br.2018.1100.","journal-title":"Biomed Rep"},{"key":"474_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2165\/00002018-200831010-00005","volume":"31","author":"TD Filippatos","year":"2008","unstructured":"Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31:53\u201365.","journal-title":"Drug Saf"},{"key":"474_CR42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/dom.14284","volume":"23","author":"HS Bajaj","year":"2021","unstructured":"Bajaj HS, Burrows M, Blavignac J, Paron E, Camacho F, Gould E, et al. Extended-release naltrexone\/bupropion and liver health: pooled, post hoc analysis from four randomized controlled trials. Diabetes Obes Metab. 2021;23:861\u20135. https:\/\/doi.org\/10.1111\/dom.14284.","journal-title":"Diabetes Obes Metab"},{"key":"474_CR43","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/dom.13655","volume":"21","author":"D Tuccinardi","year":"2019","unstructured":"Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Mathew H, Paschou SA, et al. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: a six-month, randomized, placebo-controlled, double-blind clinical trial. Diabetes Obes Metab. 2019;21:1487\u201392. https:\/\/doi.org\/10.1111\/dom.13655.","journal-title":"Diabetes Obes Metab"},{"key":"474_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733\u201394. https:\/\/doi.org\/10.1152\/physrev.00055.2009.","journal-title":"Physiol Rev"},{"key":"474_CR45","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61:2098\u2013107. https:\/\/doi.org\/10.1007\/s00125-018-4669-0.","journal-title":"Diabetologia"},{"key":"474_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174272","volume":"907","author":"ES Makri","year":"2021","unstructured":"Makri ES, Goulas A, Polyzos SA. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol. 2021;907: 174272. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174272.","journal-title":"Eur J Pharmacol"},{"key":"474_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, et al. Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21:285\u201392. https:\/\/doi.org\/10.1111\/dom.13520.","journal-title":"Diabetes Obes Metab"},{"key":"474_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","volume":"87","author":"H Tobita","year":"2017","unstructured":"Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp. 2017;87:13\u20139. https:\/\/doi.org\/10.1016\/j.curtheres.2017.07.002.","journal-title":"Curr Ther Res Clin Exp"},{"key":"474_CR49","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.diabres.2018.05.017","volume":"142","author":"N Kurinami","year":"2018","unstructured":"Kurinami N, Sugiyama S, Yoshida A, Hieshima K, Miyamoto F, Kajiwara K, et al. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;142:254\u201363. https:\/\/doi.org\/10.1016\/j.diabres.2018.05.017.","journal-title":"Diabetes Res Clin Pract"},{"key":"474_CR50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00535-017-1364-8","volume":"53","author":"Y Seko","year":"2018","unstructured":"Seko Y, Sumida Y, Sasaki K, Itoh Y, Iijima H, Hashimoto T, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 2018;53:140\u201351. https:\/\/doi.org\/10.1007\/s00535-017-1364-8.","journal-title":"J Gastroenterol"},{"key":"474_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","volume":"42","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42:25\u201332. https:\/\/doi.org\/10.1016\/j.diabet.2015.10.003.","journal-title":"Diabetes Metab"},{"key":"474_CR52","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdi.12980","volume":"10","author":"M Inoue","year":"2019","unstructured":"Inoue M, Hayashi A, Taguchi T, Arai R, Sasaki S, Takano K, et al. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2019;10:1004\u201311. https:\/\/doi.org\/10.1111\/jdi.12980.","journal-title":"J Diabetes Investig"},{"key":"474_CR53","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2147\/DMSO.S184767","volume":"11","author":"Y Seko","year":"2018","unstructured":"Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1\u20133 fibrosis. Diabetes Metab Syndr Obes. 2018;11:835\u201343. https:\/\/doi.org\/10.2147\/DMSO.S184767.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"474_CR54","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13584","volume":"21","author":"K Cusi","year":"2019","unstructured":"Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21:812\u201321. https:\/\/doi.org\/10.1111\/dom.13584.","journal-title":"Diabetes Obes Metab"},{"key":"474_CR55","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41:1801\u20138. https:\/\/doi.org\/10.2337\/dc18-0165.","journal-title":"Diabetes Care"},{"key":"474_CR56","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","volume":"61","author":"N Sattar","year":"2018","unstructured":"Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME(R) trial. Diabetologia. 2018;61:2155\u201363. https:\/\/doi.org\/10.1007\/s00125-018-4702-3.","journal-title":"Diabetologia"},{"key":"474_CR57","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/hepr.12834","volume":"47","author":"Y Seko","year":"2017","unstructured":"Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017;47:1072\u20138. https:\/\/doi.org\/10.1111\/hepr.12834.","journal-title":"Hepatol Res"},{"key":"474_CR58","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc17-0518","volume":"40","author":"D Ito","year":"2017","unstructured":"Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40:1364\u201372. https:\/\/doi.org\/10.2337\/dc17-0518.","journal-title":"Diabetes Care"},{"key":"474_CR59","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1507\/endocrj.EJ16-0295","volume":"64","author":"T Takase","year":"2017","unstructured":"Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J. 2017;64:363\u20137. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0295.","journal-title":"Endocr J"},{"key":"474_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep4.1696","volume":"6","author":"H Takahashi","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022;6:120\u201332. https:\/\/doi.org\/10.1002\/hep4.1696.","journal-title":"Hepatol Commun"},{"key":"474_CR61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/dom.13061","volume":"20","author":"T Shibuya","year":"2018","unstructured":"Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. 2018;20:438\u201342. https:\/\/doi.org\/10.1111\/dom.13061.","journal-title":"Diabetes Obes Metab"},{"key":"474_CR62","doi-asserted-by":"publisher","unstructured":"Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, et al. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Res Care. 2021;9. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001990.","DOI":"10.1136\/bmjdrc-2020-001990"},{"key":"474_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3413","volume":"37","author":"FDS Coelho","year":"2021","unstructured":"Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, et al. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials. Diabetes Metab Res Rev. 2021;37: e3413. https:\/\/doi.org\/10.1002\/dmrr.3413.","journal-title":"Diabetes Metab Res Rev"},{"key":"474_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.609135","volume":"11","author":"C Wong","year":"2020","unstructured":"Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, et al. Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in asian patients with type 2 diabetes: a meta-analysis. Front Endocrinol (Lausanne). 2020;11: 609135. https:\/\/doi.org\/10.3389\/fendo.2020.609135.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"474_CR65","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/osp4.294","volume":"4","author":"T Itani","year":"2018","unstructured":"Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract. 2018;4:477\u201382. https:\/\/doi.org\/10.1002\/osp4.294.","journal-title":"Obes Sci Pract"},{"key":"474_CR66","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40261-016-0383-1","volume":"36","author":"T Ohki","year":"2016","unstructured":"Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clin Drug Investig. 2016;36:313\u20139. https:\/\/doi.org\/10.1007\/s40261-016-0383-1.","journal-title":"Clin Drug Investig"},{"key":"474_CR67","doi-asserted-by":"publisher","unstructured":"Ng CH, Lin SY, Chin YH, Lee MH, Syn N, Goh XL, et al. Anti-diabetic medications for type 2 diabetics with non-alcoholic fatty liver disease. Evidence from a network meta-analysis of randomised controlled trials. Endocr Pract. 2022;28:223\u201330. https:\/\/doi.org\/10.1016\/j.eprac.2021.09.013.","DOI":"10.1016\/j.eprac.2021.09.013"},{"key":"474_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-021-01272-z","volume":"20","author":"C Zheng","year":"2021","unstructured":"Zheng C, Lin M, Chen Y, Xu H, Yan L, Dai H. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2021;20:83. https:\/\/doi.org\/10.1186\/s12933-021-01272-z.","journal-title":"Cardiovasc Diabetol"},{"key":"474_CR69","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","volume":"79","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64\u201376. https:\/\/doi.org\/10.1016\/j.metabol.2017.11.003.","journal-title":"Metabolism"},{"key":"474_CR70","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","volume":"106","author":"DS Lin","year":"2021","unstructured":"Lin DS, Lee JK, Chen WJ. Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab. 2021;106:2133\u201345. https:\/\/doi.org\/10.1210\/clinem\/dgab274.","journal-title":"J Clin Endocrinol Metab"},{"key":"474_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172661","volume":"863","author":"V Venetsanaki","year":"2019","unstructured":"Venetsanaki V, Karabouta Z, Polyzos SA. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. Eur J Pharmacol. 2019;863: 172661. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172661.","journal-title":"Eur J Pharmacol"},{"key":"474_CR72","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-82.e1. https:\/\/doi.org\/10.1053\/j.gastro.2013.05.042.","journal-title":"Gastroenterology"},{"key":"474_CR73","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/s0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u201365. https:\/\/doi.org\/10.1016\/s0140-6736(14)61933-4.","journal-title":"Lancet"},{"key":"474_CR74","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/s0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(19)33041-7.","journal-title":"Lancet"},{"key":"474_CR75","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.16583","volume":"54","author":"AM Majzoub","year":"2021","unstructured":"Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, et al. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021;54:880\u20139. https:\/\/doi.org\/10.1111\/apt.16583.","journal-title":"Aliment Pharmacol Ther"},{"key":"474_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154144","volume":"104","author":"SA Polyzos","year":"2020","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: expectations and concerns. Metabolism. 2020;104: 154144. https:\/\/doi.org\/10.1016\/j.metabol.2020.154144.","journal-title":"Metabolism"},{"key":"474_CR77","doi-asserted-by":"publisher","DOI":"10.2174\/1570161119666211209161023","author":"SA Polyzos","year":"2021","unstructured":"Polyzos SA, Xanthopoulos K, Kountouras J. Cilofexor for the treatment of nonalcoholic steatohepatitis. Curr Vasc Pharmacol. 2021. https:\/\/doi.org\/10.2174\/1570161119666211209161023.","journal-title":"Curr Vasc Pharmacol"},{"key":"474_CR78","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","volume":"72","author":"K Patel","year":"2020","unstructured":"Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology. 2020;72:58\u201371. https:\/\/doi.org\/10.1002\/hep.31205.","journal-title":"Hepatology"},{"key":"474_CR79","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14209","volume":"39","author":"PJ Pockros","year":"2019","unstructured":"Pockros PJ, Fuchs M, Freilich B, Schiff E, Kohli A, Lawitz EJ, et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019;39:2082\u201393. https:\/\/doi.org\/10.1111\/liv.14209.","journal-title":"Liver Int"},{"key":"474_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105649","volume":"169","author":"A Cignarella","year":"2021","unstructured":"Cignarella A, Busetto L, Vettor R. Pharmacotherapy of obesity: an update. Pharmacol Res. 2021;169: 105649. https:\/\/doi.org\/10.1016\/j.phrs.2021.105649.","journal-title":"Pharmacol Res"},{"key":"474_CR81","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/s0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583\u201398. https:\/\/doi.org\/10.1016\/s0140-6736(21)01443-4.","journal-title":"Lancet"},{"key":"474_CR82","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"key":"474_CR83","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43:1352\u20135. https:\/\/doi.org\/10.2337\/dc19-1892.","journal-title":"Diabetes Care"},{"key":"474_CR84","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1463-1326.2009.01176.x","volume":"12","author":"SA Polyzos","year":"2010","unstructured":"Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365\u201383.","journal-title":"Diabetes Obes Metab"},{"key":"474_CR85","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/s0140-6736(18)30726-8","volume":"391","author":"P Ambery","year":"2018","unstructured":"Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391:2607\u201318. https:\/\/doi.org\/10.1016\/s0140-6736(18)30726-8.","journal-title":"Lancet"},{"key":"474_CR86","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","volume":"2","author":"ML Boland","year":"2020","unstructured":"Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020;2:413\u201331. https:\/\/doi.org\/10.1038\/s42255-020-0209-6.","journal-title":"Nat Metab"},{"key":"474_CR87","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","volume":"44","author":"R Nahra","year":"2021","unstructured":"Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care. 2021;44:1433\u201342. https:\/\/doi.org\/10.2337\/dc20-2151.","journal-title":"Diabetes Care"},{"key":"474_CR88","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","volume":"26","author":"MM Jepsen","year":"2021","unstructured":"Jepsen MM, Christensen MB. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021;26:231\u201343. https:\/\/doi.org\/10.1080\/14728214.2021.1947240.","journal-title":"Expert Opin Emerg Drugs"},{"key":"474_CR89","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.29897","volume":"68","author":"SA Polyzos","year":"2018","unstructured":"Polyzos SA, Kountouras J, Anastasiadis S, Doulberis M, Katsinelos P. Nonalcoholic fatty liver disease: is it time for combination treatment and a diabetes-like approach? Hepatology. 2018;68:389. https:\/\/doi.org\/10.1002\/hep.29897.","journal-title":"Hepatology"},{"key":"474_CR90","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.metabol.2016.05.013","volume":"65","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism. 2016;65:1297\u2013306. https:\/\/doi.org\/10.1016\/j.metabol.2016.05.013.","journal-title":"Metabolism"},{"key":"474_CR91","doi-asserted-by":"publisher","unstructured":"Nakanishi N, Hashimoto Y, Okamura T, Ohbora A, Kojima T, Hamaguchi M, et al. A weight regain of 1.5\u00a0kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. Sci Rep. 2021;11:19992. https:\/\/doi.org\/10.1038\/s41598-021-99036-y.","DOI":"10.1038\/s41598-021-99036-y"},{"key":"474_CR92","doi-asserted-by":"crossref","unstructured":"Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication. Clin Pharmacol Ther. 1992;51:615\u20138.","DOI":"10.1038\/clpt.1992.73"},{"key":"474_CR93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s42000-021-00339-6","volume":"21","author":"I Vachliotis","year":"2021","unstructured":"Vachliotis I, Goulas A, Papaioannidou P, Polyzos SA. Nonalcoholic fatty liver disease: lifestyle and quality of life. Hormones (Athens). 2021. https:\/\/doi.org\/10.1007\/s42000-021-00339-6.","journal-title":"Hormones (Athens)"},{"key":"474_CR94","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005\u201323.","journal-title":"Hepatology"},{"key":"474_CR95","doi-asserted-by":"publisher","unstructured":"EASL\u2013EASD\u2013EASO. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121\u201340. https:\/\/doi.org\/10.1007\/s00125-016-3902-y.","DOI":"10.1007\/s00125-016-3902-y"},{"key":"474_CR96","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/jgh.13856","volume":"33","author":"S Chitturi","year":"2018","unstructured":"Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, et al. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-part 2: management and special groups. J Gastroenterol Hepatol. 2018;33:86\u201398. https:\/\/doi.org\/10.1111\/jgh.13856.","journal-title":"J Gastroenterol Hepatol"},{"key":"474_CR97","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1210\/jc.2009-2128","volume":"95","author":"D Heber","year":"2010","unstructured":"Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C, et al. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95:4823\u201343. https:\/\/doi.org\/10.1210\/jc.2009-2128.","journal-title":"J Clin Endocrinol Metab"},{"key":"474_CR98","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1040\u201360. https:\/\/doi.org\/10.1016\/j.cgh.2018.10.017.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-022-00474-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-022-00474-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-022-00474-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T01:54:25Z","timestamp":1661219665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-022-00474-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":98,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1007\/s13679-022-00474-0","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"11 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"SAP: No conflict of interest. DGG: No conflict of interest. OG: No conflict of interest. GSG: No conflict of interest. AG: No conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors. Therefore, a signed informed consent is not applied for this narrative review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}